Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of adding cyclophosphamide or lenalidomide to bortezomib + dexamethasone in relapsed or refractory multiple myeloma
2007-001462-33Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, cyclophosphamide, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall response rate. Started Oct 2007; status: completed.
02
Drugs
bortezomibcyclophosphamidelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-001462-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001462-33.